Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
WELCHOL vs FLAVORED COLESTID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Welchol (colesevelam) is a bile acid sequestrant. It binds to bile acids in the intestine, forming an insoluble complex that is excreted in the feces. This disrupts the enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, resulting in decreased serum low-density lipoprotein cholesterol (LDL-C). Additionally, colesevelam may improve glycemic control in type 2 diabetes by binding to bile acids, which alters farnesoid X receptor (FXR) and TGR5 signaling, leading to increased glucagon-like peptide-1 (GLP-1) secretion and improved insulin sensitivity.
Colestid (colestipol) is a bile acid sequestrant. It binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, thereby lowering serum low-density lipoprotein (LDL) cholesterol levels.
Primary hyperlipidemia (Fredrickson type IIa and IIb) as monotherapy or in combination with an HMG-Co A reductase inhibitor (statin) to reduce LDL-C,Adjunctive therapy for heterozygous familial hypercholesterolemia in pediatric patients aged 10-17 years,Improvement of glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
Adjunctive therapy for reduction of elevated serum total and LDL cholesterol in patients with primary hypercholesterolemia (Fredrickson Type IIa) who do not respond adequately to diet,Pruritus associated with partial biliary obstruction,Off-label: Digoxin toxicity, pseudomembranous colitis, methotrexate toxicity
Adults: 625 mg to 1.875 g orally twice daily, with meals. Maximum 4.375 g/day.
5-30 grams orally daily, divided into 2-4 doses, starting at 5 grams once daily and increasing by 5 grams every 4-7 days as tolerated; taken with meals and mixed with at least 4-8 oz of liquid per dose.
Not applicable; colesevelam acts locally in the gastrointestinal tract and is not absorbed systemically. Terminal half-life is not measurable in conventional pharmacokinetic sense due to negligible systemic absorption.
Not applicable due to non-absorbable resin; systemic absorption is negligible. Terminal half-life not defined.
Colesevelam is not absorbed systemically and therefore not metabolized by hepatic cytochrome P450 enzymes. It acts locally in the gastrointestinal tract and is excreted unchanged in the feces.
Colestipol is not absorbed systemically; it acts locally in the gastrointestinal tract and is excreted unchanged in feces.
Primarily fecal as unchanged drug (approximately 85%), with less than 0.5% renal excretion of absorbed drug; no biliary excretion due to non-absorbed nature.
Primarily fecal as insoluble complex (90-95%); <5% renal as glucuronide conjugate; minimal biliary elimination.
<0.1% (negligible systemic absorption results in minimal protein binding; colesevelam is a non-absorbed polymer).
Does not bind to plasma proteins as it is not absorbed.
Not applicable (colesevelam is not systemically absorbed; Vd cannot be determined and is clinically irrelevant).
Not applicable; minimal systemic absorption (Vd essentially 0).
Oral bioavailability <0.5% (negligible systemic absorption); drug acts locally in gastrointestinal tract.
Oral bioavailability is <0.05% via absorption; acts locally in GI tract.
No dose adjustment needed for renal impairment.
No specific recommendations; use caution in severe renal impairment due to potential accumulation of inactive ingredients. GFR <30 m L/min: consider alternative agents or reduced dose under clinical monitoring.
Not recommended in patients with bowel obstruction or severe hepatic impairment; no specific Child-Pugh guidelines.
No specific guidelines for Child-Pugh scores; no expected alterations in pharmacokinetics as drug is not systemically absorbed. Use with caution in severe hepatic impairment due to potential electrolyte disturbances.
Not approved for use in pediatric patients.
Not established for children under 18 years; safety and efficacy not determined. In adolescents (≥18 years) use adult dosing titrated to effect with close monitoring.
No specific dose adjustment; use with caution due to potential constipation.
Start at low end of dosing range (5 grams once daily); titrate slowly. Monitor for constipation, electrolyte imbalances, and drug interactions. No specific age-based dose adjustments recommended.
None
Not applicable (no FDA black box warning).
May increase serum triglycerides; use with caution in patients with hypertriglyceridemia, particularly when triglyceride levels exceed 300 mg/d L, as it may cause severe hypertriglyceridemia and pancreatitis.,May decrease absorption of fat-soluble vitamins (A, D, E, K) and folic acid; monitor and consider supplementation if necessary.,May cause gastrointestinal adverse effects such as constipation, dyspepsia, and abdominal pain; patients should be advised to increase fluid and fiber intake.,May reduce absorption of orally administered drugs; administer other medications at least 4 hours before Welchol or consider separating by longer intervals.,Use with caution in patients with swallowing disorders or gastrointestinal motility disorders.,Not recommended for patients with pre-existing hypertriglyceridemia (triglycerides >500 mg/d L) due to risk of severe elevation.
Can cause hypertriglyceridemia; caution in patients with pre-existing hypertriglyceridemia. Risk of fat-soluble vitamin deficiency (A, D, E, K) with long-term use. May interfere with absorption of other medications; administer other drugs at least 1 hour before or 4 hours after colestipol. Constipation may worsen hemorrhoids. Use caution in patients with gastrointestinal motility disorders or history of bowel obstruction.
History of hypersensitivity to colesevelam or any component of the formulation,Bowel obstruction,Serum triglyceride level >500 mg/d L
Complete biliary obstruction (contraindicated because ineffective). Hypersensitivity to colestipol or any component of the formulation.
Take with meals to enhance binding of bile acids. Avoid high-fat meals if triglycerides elevated. No specific food restrictions beyond general healthy diet.
Take with meals to enhance efficacy. Avoid high-fat meals as they reduce binding capacity. Mix with non-carbonated beverages or soft foods; do not take dry. Can be mixed with orange juice without affecting efficacy. May reduce absorption of fat-soluble vitamins; consider vitamin supplementation if long-term therapy.
Welchol (colesevelam) is a bile acid sequestrant. In animal studies, no evidence of teratogenicity was observed at doses up to 3 times the human dose. Human data are limited. The drug is not absorbed systemically, so fetal exposure is negligible. However, it may reduce absorption of fat-soluble vitamins (A, D, E, K), which are essential for fetal development. Insufficient vitamin K can cause neonatal coagulopathy. Therefore, potential risk of fetal harm is low but theoretical if maternal vitamin deficiency occurs. FDA Pregnancy Category B.
Colestid (colestipol) is not systemically absorbed; therefore, no fetal exposure is expected. No teratogenic effects have been reported in animal studies or human data. However, use during pregnancy may impair absorption of fat-soluble vitamins (A, D, E, K), potentially affecting fetal development. Trimester-specific risks: First trimester: theoretical risk of vitamin deficiency. Second and third trimesters: risk of vitamin K deficiency leading to neonatal hemorrhage. Overall, the drug is considered low risk due to lack of systemic absorption.
Colesevelam is not absorbed systemically and is not expected to be excreted into breast milk. No human studies are available. The M/P ratio is unknown but likely extremely low due to lack of absorption. Caution is advised, but risk to nursing infant is minimal. Monitor infant for signs of vitamin deficiency if mother is on long-term therapy.
Colestid is not absorbed systemically, so it is unlikely to be excreted into breast milk. No data on M/P ratio. It is considered compatible with breastfeeding, but caution is advised due to potential interference with maternal absorption of fat-soluble vitamins, which could affect milk composition. Monitor infant for signs of vitamin deficiency.
No pharmacokinetic changes are reported for colesevelam in pregnancy as it is not absorbed. Standard dosing may be used, but ensure adequate supplementation of fat-soluble vitamins, especially vitamins A, D, E, and K. Dose adjustments are not required based on pregnancy status alone. Monitor for constipation, which may be exacerbated in pregnancy.
No dose adjustment is required due to lack of systemic absorption. However, ensure adequate supplementation of fat-soluble vitamins (A, D, E, K) and folic acid, as colestipol may reduce their absorption. Administer colestipol and vitamin supplements at least 4–6 hours apart to minimize interaction.
Administer Welchol at least 4 hours after other medications to avoid binding and reducing absorption. Monitor LDL-C reduction at 4-6 weeks; may increase triglycerides. Contraindicated in history of hypertriglyceridemia-induced pancreatitis.
Flavored Colestid (colestipol) is a bile acid sequestrant used as adjunctive therapy to diet for reduction of elevated serum total and LDL cholesterol. Administer with meals to maximize binding of bile acids. Mix with liquids (water, juice, milk) or soft foods (applesauce, crushed pineapple). Avoid concurrent administration with other medications; give at least 1 hour before or 4 hours after other oral drugs to reduce interference with absorption. Monitor for constipation, which can be severe; increase fluid intake. May reduce absorption of fat-soluble vitamins (A, D, E, K); consider supplementation in long-term therapy.
Take Welchol with a meal and plenty of water.,Take other medications at least 4 hours before or after Welchol.,Do not crush or chew the tablets; swallow whole.,May cause constipation; increase fluid and fiber intake.,Report severe stomach pain or triglyceridemia symptoms.
Take this medication with meals and plenty of water to prevent constipation.,Mix the powder with at least 3-6 ounces of liquid (water, juice, milk) or soft food (applesauce, crushed pineapple) and drink immediately.,Do not take other medications at the same time; take them at least 1 hour before or 4 hours after colestipol.,Common side effects include constipation, bloating, and gas; increase fiber and fluid intake to help.,Contact your doctor if you have severe stomach pain, rectal bleeding, or signs of vitamin deficiency (unusual bruising, bone pain).,Continued adherence to cholesterol-lowering diet and exercise is essential.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about WELCHOL vs FLAVORED COLESTID, answered by our medical review team.
WELCHOL is a Bile Acid Sequestrant that works by Welchol (colesevelam) is a bile acid sequestrant. It binds to bile acids in the intestine, forming an insoluble complex that is excreted in the feces. This disrupts the enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, resulting in decreased serum low-density lipoprotein cholesterol (LDL-C). Additionally, colesevelam may improve glycemic control in type 2 diabetes by binding to bile acids, which alters farnesoid X receptor (FXR) and TGR5 signaling, leading to increased glucagon-like peptide-1 (GLP-1) secretion and improved insulin sensitivity.. FLAVORED COLESTID is a Bile Acid Sequestrant that works by Colestid (colestipol) is a bile acid sequestrant. It binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, thereby lowering serum low-density lipoprotein (LDL) cholesterol levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between WELCHOL and FLAVORED COLESTID depend on the specific clinical indication. These are both Bile Acid Sequestrant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of WELCHOL is: Adults: 625 mg to 1.875 g orally twice daily, with meals. Maximum 4.375 g/day.. The standard adult dose of FLAVORED COLESTID is: 5-30 grams orally daily, divided into 2-4 doses, starting at 5 grams once daily and increasing by 5 grams every 4-7 days as tolerated; taken with meals and mixed with at least 4-8 oz of liquid per dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between WELCHOL and FLAVORED COLESTID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. WELCHOL is classified as Category C. Welchol (colesevelam) is a bile acid sequestrant. In animal studies, no evidence of teratogenicity was observed at doses up to 3 times the human dose. Human data are limited. The d. FLAVORED COLESTID is classified as Category C. Colestid (colestipol) is not systemically absorbed; therefore, no fetal exposure is expected. No teratogenic effects have been reported in animal studies or human data. However, us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.